Science. Partners. Progress.

Kevin brings extensive experience integrating population-scale multi-omics datasets using advanced genetic epidemiology methods, with research focused on Type 2 Diabetes and CKD. At 5Prime, he will contribute to data engineering initiatives and multi-omics integration.

Alec's work sits at the intersection of human genetics, the gut microbiome, and applied genetic epidemiology. He brings experience from AstraZeneca's Machine Learning and Data Science Oncology group, and contributes to analytical method development and client programs at 5Prime.

5Prime and Dexoligo are collaborating to identify genetically supported, liver-expressed targets for development using GalNAc-siRNA therapeutics, combining human genetic evidence with a delivery technology designed for hepatic targets.

Peter brings over a decade of experience building bioinformatics tools and pipelines, most recently at the Public Health Agency of Canada, where he developed open-source workflows including the widely-used SISTR tool. He will focus on designing and integrating Nextflow pipelines at 5Prime.

Numab Therapeutics AG develops multi-specific antibody-based immunotherapies for inflammation and cancer. 5Prime's human genetic evidence will support target selection and validation within their discovery programs.

Platform talk on ANGPTL4 and remnant cholesterol. Posters on Trajecta (autoimmune progression), DrugTargetSuccess (clinical success prediction), PRIMEx (causal gene identification), and the communication of genetic evidence to drug developers.

5Prime provided genetic evidence validating ANGPTL4 and comparing it against alternative triglyceride-lowering mechanisms in Lipigon's early-stage work. Lipisense® has now advanced to Phase II. A direct outcome of that early biological validation.

The latest version of PRIMEx, 5Prime's machine learning approach to causal gene identification, demonstrates AUROC of 0.75 and AUPRC of 0.93, outperforming Open Targets L2G on precision and recall in independent benchmarks. White paper forthcoming.

5Prime and Eli Lilly are collaborating to accelerate target discovery and early development in cardio-metabolic disease, applying 5Prime's human genetics and multi-omics capabilities to Lilly's pipeline.

Scientists at 5Prime and GSK are developing novel methodologies to advance human genetics in R&D decision-making, with a focus on new methods that go beyond standard genetics workflows for target identification and validation.